Trending...
- Mayor Michelle Wu and Office of Youth Engagement and Advancement Celebrate 30 Years of Boston Mayor's Youth Council
- Boston: Community Meeting to Share a Progress Update for the New Community Center in the North End
- Boston: Cummins Highway Construction Update: June 2025
NEW YORK, June 9, 2025 ~ Formation Bio, a leading AI-driven pharmaceutical company, has announced the appointment of its first class of Entrepreneurs in Residence (EIRs). The four seasoned dealmakers, Kia Motesharei, Ph.D., Minji Kim Ph.D, MBA, John Taylor, M.S., and Anthony S. Walsh, D.Phil, will work closely with Chief Business Officer David Steinberg to expand the company's business development capabilities and further its mission to accelerate drug development and bring high-potential treatments to patients faster.
Formation Bio is known for acquiring and in-licensing promising drug assets and advancing them through critical development milestones. Their AI platform supports this end-to-end process, from asset identification to execution of clinical trials. With the addition of the EIRs, Formation Bio aims to strengthen its pipeline through strategic partnerships and licensing deals.
The EIR program at Formation Bio offers a unique opportunity for experienced dealmakers to deploy capital through an innovative model. Each of the newly appointed EIRs brings extensive experience in sourcing and executing high-value biopharma transactions. This reflects Formation Bio's commitment to investing in growing its pipeline and unlocking value for patients.
More on Boston Chron
According to David Steinberg, Chief Business Officer at Formation Bio, the biotech industry is at a crucial point where breakthrough science is abundant but funding and resources are scarce. He believes that Formation Bio can bridge this gap with its capital, drug development capabilities, model, and platform. Steinberg expresses his excitement about welcoming the EIRs and their ability to go deep on science they believe in and advance transformative medicines.
Combining proprietary technology with deep domain expertise, Formation Bio's teams uncover overlooked or underdeveloped promising programs to transact on and develop. The EIRs will play a crucial role in this work with their decades of dealmaking experience and industry connectivity. They will also bring their expertise in various therapeutic areas such as NASH/MASH, Korea/APAC, rare diseases, and immunology & inflammation (I&I).
The diverse focus areas of the EIRs will strengthen Formation Bio's ability to identify and unlock high-value opportunities across a wide range of modalities and markets. Their arrival also reflects the company's growing presence in key industry hubs like Boston and North Carolina, where they are deepening ties with leading talent, companies, and partners across the biotech and pharma ecosystem.
In conclusion, the appointment of these four highly experienced EIRs at Formation Bio highlights the company's commitment to accelerating drug development and bringing innovative treatments to patients. With their expertise and Formation Bio's AI platform, the company is well-positioned to make significant strides in the biotech industry.
Formation Bio is known for acquiring and in-licensing promising drug assets and advancing them through critical development milestones. Their AI platform supports this end-to-end process, from asset identification to execution of clinical trials. With the addition of the EIRs, Formation Bio aims to strengthen its pipeline through strategic partnerships and licensing deals.
The EIR program at Formation Bio offers a unique opportunity for experienced dealmakers to deploy capital through an innovative model. Each of the newly appointed EIRs brings extensive experience in sourcing and executing high-value biopharma transactions. This reflects Formation Bio's commitment to investing in growing its pipeline and unlocking value for patients.
More on Boston Chron
- Boston: Updates on Transformative Investments in Mental Health Services and Programs for Youth and Families
- AI changes cryptocurrency market trading, TWL Miner launches new 1-day contract, giving away over $1 million
- King Faisal Specialist Hospital & Research Centre and Germfree Laboratories Announce Landmark Advanced Therapy Manufacturing Campus in Riyadh
- Labthink's Medford Lab is Open for Testing Services for Flexible Packaging Materials
- A Global First: NaturismRE™ Launches the Global Urgency Index
According to David Steinberg, Chief Business Officer at Formation Bio, the biotech industry is at a crucial point where breakthrough science is abundant but funding and resources are scarce. He believes that Formation Bio can bridge this gap with its capital, drug development capabilities, model, and platform. Steinberg expresses his excitement about welcoming the EIRs and their ability to go deep on science they believe in and advance transformative medicines.
Combining proprietary technology with deep domain expertise, Formation Bio's teams uncover overlooked or underdeveloped promising programs to transact on and develop. The EIRs will play a crucial role in this work with their decades of dealmaking experience and industry connectivity. They will also bring their expertise in various therapeutic areas such as NASH/MASH, Korea/APAC, rare diseases, and immunology & inflammation (I&I).
The diverse focus areas of the EIRs will strengthen Formation Bio's ability to identify and unlock high-value opportunities across a wide range of modalities and markets. Their arrival also reflects the company's growing presence in key industry hubs like Boston and North Carolina, where they are deepening ties with leading talent, companies, and partners across the biotech and pharma ecosystem.
In conclusion, the appointment of these four highly experienced EIRs at Formation Bio highlights the company's commitment to accelerating drug development and bringing innovative treatments to patients. With their expertise and Formation Bio's AI platform, the company is well-positioned to make significant strides in the biotech industry.
Filed Under: Business
0 Comments
Latest on Boston Chron
- Boston: MAYOR WU AND CITY OF BOSTON PROVIDE UPDATES ON MENTAL HEALTH SERVICES AND PROGRAMS FOR YOUTH AND FAMILIES
- Co-founder of AlphaRoute Honored by MIT for Advancing Operational Efficiency
- Boston: Mayor's Cup Flag Football Tournament Begins July 26
- PUSHERMAN- – Best Feature Documentary Official Winner at NYC and London Festivals
- Female Motorsports Sponsorship & Expansion; Acquisition Agreement of UAE-Based Sports Incubator by Online Lottery & Sports Game Provider: Lottery.com
- Boston: New Legal Services Grants and Resources to Better Support LGBTQ+ Residents
- Global Court Momentum Builds Against Forced Psychiatry; CCHR Urges U.S. Reform
- Big4Bio and BYTE51 Announce Partnership at 2025 BIO International Convention to Make Life Sciences Intelligence Accessible to All
- Integris Composites Joins Paris Air Show at USA Pavilion
- Cheryl Hines' Trailer PROWLING to Sardinia
- Honoring Black History, Culture, and Community in Fall River
- Token-Operated Sake Service Opens at Tobu Nikko Station
- Person with Measles Visited Boston
- Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
- Boston: Mayor Michelle Wu and LGBTQ+ Advancement Announce New Legal Services Grants and Resources to Better Support LGBTQ+ Residents
- A Living Legacy – New Short Film Honors George Floyd, Premieres on YouTube
- Boston: June 13, 2025 Traffic Advisory
- Boston: Planning Department Advances New Cancer Hospital In Longwood Medical Area
- DivX Enhances AVI Playback Resources; Simplifies Guide to Playing AVI Files with DivX Software
- Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake